Answers are grounded in this paper and cite their sources.
Compared to anti-D alloimmunization, anti-E alloimmunization is a less common cause of hemolytic diseases of the newborn. Being a less potent immunogen, clinical manifestations of anti-E alloimmunization are more variable and usually of less severity. However, the clinical obstetric management of these cases of anti-E alloimmunization is just as challenging. We report here the management of a patient with anti-E alloimmunization to illustrate the controversies of invasive and non-invasive monitoring in the management of such cases.
No takes yet. Share an insight, caveat, or question.
To et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: